Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma By Ogkologos - June 18, 2025 705 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Neoadjuvant Pertuzumab/Trastuzumab Demonstrates Long-Term Cardiac Safety in HER2-Positive Breast Cancer May 7, 2021 Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... March 17, 2025 Could proton beam therapy improve throat cancer treatment? March 15, 2021 County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19 March 17, 2020 Load more HOT NEWS Silence Speaks Volumes Virtual Reality Could Reduce Stress for Chemo Patients, Improving Cancer Outcomes Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than... On World Cancer Day, ESMO Renews a Longstanding Commitment to Closing...
